Title |
Constructing narratives of heroism and villainy: case study of Myriad's BRACAnalysis® compared to Genentech's Herceptin®
|
---|---|
Published in |
Genome Medicine, January 2013
|
DOI | 10.1186/gm412 |
Pubmed ID | |
Authors |
A Lane Baldwin, Robert Cook-Deegan |
Abstract |
The development of Herceptin(®) is welcomed as a major advance in breast cancer treatment, while Myriad's development of BRACAnalysis(®) is a widely used diagnostic. However useful and successful this product is, its presence in the public eye is tainted by predominantly negative press about gene patenting and business practices. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 33% |
Unknown | 4 | 67% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 50% |
Scientists | 2 | 33% |
Practitioners (doctors, other healthcare professionals) | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 3% |
Unknown | 37 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 7 | 18% |
Student > Master | 7 | 18% |
Researcher | 6 | 16% |
Other | 4 | 11% |
Student > Ph. D. Student | 3 | 8% |
Other | 4 | 11% |
Unknown | 7 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 9 | 24% |
Social Sciences | 5 | 13% |
Agricultural and Biological Sciences | 5 | 13% |
Unspecified | 2 | 5% |
Engineering | 2 | 5% |
Other | 8 | 21% |
Unknown | 7 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 March 2014.
All research outputs
#7,218,997
of 25,413,176 outputs
Outputs from Genome Medicine
#1,157
of 1,587 outputs
Outputs of similar age
#71,914
of 291,014 outputs
Outputs of similar age from Genome Medicine
#17
of 23 outputs
Altmetric has tracked 25,413,176 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 1,587 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 26.8. This one is in the 26th percentile – i.e., 26% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 291,014 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.